Eagle Asset Management Inc. boosted its stake in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 0.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 980,673 shares of the company’s stock after buying an additional 8,081 shares during the period. Eagle Asset Management Inc. owned approximately 3.40% of Atara Biotherapeutics worth $20,976,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ATRA. ProShare Advisors LLC increased its stake in Atara Biotherapeutics by 4.2% in the second quarter. ProShare Advisors LLC now owns 24,236 shares of the company’s stock valued at $546,000 after buying an additional 980 shares during the period. JPMorgan Chase & Co. increased its stake in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock valued at $1,191,000 after buying an additional 1,900 shares during the period. BlackRock Advisors LLC increased its stake in Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock valued at $229,000 after buying an additional 2,361 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock valued at $365,000 after buying an additional 3,100 shares during the period. Finally, American International Group Inc. increased its stake in Atara Biotherapeutics by 30.3% in the second quarter. American International Group Inc. now owns 13,371 shares of the company’s stock valued at $301,000 after buying an additional 3,111 shares during the period. 77.18% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded up 0.25% on Tuesday, reaching $19.95. The company’s stock had a trading volume of 36,271 shares. The company’s market capitalization is $575.76 million. The firm’s 50 day moving average price is $16.77 and its 200-day moving average price is $19.75. Atara Biotherapeutics Inc. has a 1-year low of $12.45 and a 1-year high of $39.28.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.10. Equities analysts forecast that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Eagle Asset Management Inc. Purchases 8,081 Shares of Atara Biotherapeutics Inc. (ATRA)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/29/eagle-asset-management-inc-purchases-8081-shares-of-atara-biotherapeutics-inc-atra.html.

A number of research analysts have recently issued reports on ATRA shares. Jefferies Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the company a “buy” rating in a report on Sunday, November 6th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and lowered their price target for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. upped their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $25.86.

In other news, insider Mitchall G. Clark sold 2,995 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $19.53, for a total transaction of $58,492.35. Following the completion of the sale, the insider now directly owns 98,182 shares in the company, valued at approximately $1,917,494.46. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO John Mcgrath sold 5,000 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $17.47, for a total transaction of $87,350.00. Following the sale, the chief financial officer now owns 96,823 shares of the company’s stock, valued at $1,691,497.81. The disclosure for this sale can be found here. Insiders own 16.10% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.